To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:8 Issue:10 Number:20 ISSN#:2564-2537
ACE Report #12046
Ace Report Cover Trauma

OTA 2019: No significant difference with bupivacaine injection at surgical site in hip fractures

How to Cite

OrthoEvidence. OTA 2019: No significant difference with bupivacaine injection at surgical site in hip fractures. ACE Report. 2019;8(10):20. Available from:

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

A Multicenter Randomized Trial Evaluating Liposomal Bupivacaine for Decrease of Narcotic Use in Hip Fractures

Contributing Authors:
Paul Edward Matuszewski Arun Aneja AD Diwan M Kraus Eric Scott Moghadamian J Siegel R Wright Eric F Swart

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


Hip fractures are very common, and pain management is an issue. Pain itself can cause this pre-disposed population to experience confusion and delirium. On the other hand, opioid medications often used to treat the pain can often have the same effects. Thus, efficacious non-opioid pain management strategies are of great interest in hip fracture patients. The investigators randomized 55 patients to...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.